Jump to content

CEACAM5

From Wikipedia, the free encyclopedia
(Redirected from CD66e)
CEACAM5
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesCEACAM5, CD66e, CEA, carcinoembryonic antigen related cell adhesion molecule 5, CEA cell adhesion molecule 5
External IDsOMIM: 114890; HomoloGene: 128801; GeneCards: CEACAM5; OMA:CEACAM5 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001291484
NM_001308398
NM_004363

n/a

RefSeq (protein)

NP_001278413
NP_001295327
NP_004354

n/a

Location (UCSC)Chr 19: 41.71 – 41.73 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a member of the carcinoembryonic antigen (CEA) gene family.[3]

Functions

[edit]

In the literature, CEACAM5 is often used as a synonym for cancer embryonic antigen (CEA), a well-known biomarker of many types of malignancies, such as colorectal cancer and non-small-cell lung cancer.[4][5] Its primary function in the embryonic intestine and colon tumors is adhesion between epithelial cells.[6] Also, it plays a significant role in the inhibition of differentiation [7] and apoptosis [8] in colon cells. There are evidences that high CEACAM5 expression is firmly associated with the CD133-positive colorectal cancer stem cells.[9] High CEACAM5 expression has also been identified in ~25% of patients with advanced non-squamous (NSq) non-small cell lung cancer (NSCLC) detectable via IHC (immunohistochemistry).[10][11]

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000105388Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Entrez Gene: CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5".
  4. ^ Beauchemin N, Arabzadeh A (December 2013). "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis". Cancer and Metastasis Reviews. 32 (3–4): 643–671. doi:10.1007/s10555-013-9444-6. PMID 23903773. S2CID 10344352.
  5. ^ Zhang X, Han X, Zuo P, Zhang X, Xu H (September 2020). "CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration". The Journal of International Medical Research. 48 (9): 300060520959478. doi:10.1177/0300060520959478. PMC 7536504. PMID 32993395.
  6. ^ Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (April 1989). "Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule". Cell. 57 (2): 327–334. doi:10.1016/0092-8674(89)90970-7. PMID 2702691. S2CID 30740594.
  7. ^ Ilantzis C, DeMarte L, Screaton RA, Stanners CP (2002). "Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation". Neoplasia. 4 (2): 151–163. doi:10.1038/sj.neo.7900201. PMC 1550325. PMID 11896570.
  8. ^ Ordoñez C, Screaton RA, Ilantzis C, Stanners CP (July 2000). "Human carcinoembryonic antigen functions as a general inhibitor of anoikis". Cancer Research. 60 (13): 3419–3424. PMID 10910050.
  9. ^ Gisina A, Novikova S, Kim Y, Sidorov D, Bykasov S, Volchenko N, et al. (2021-01-01). "CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells". Cancer Biomarkers. 32 (1): 85–98. doi:10.3233/CBM-203187. PMID 34092615. S2CID 235359543.
  10. ^ LaPointe N, Hertle N, Hsu SC, Kellis J, King N, Littrell J, et al. (2021-05-20). "Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701)". Journal of Clinical Oncology. 39 (15_suppl): e21030. doi:10.1200/JCO.2021.39.15_suppl.e21030. ISSN 0732-183X. S2CID 236398737.
  11. ^ Kim YJ, Li W, Zhelev DV, Mellors JW, Dimitrov DS, Baek DS (2023-02-27). "Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates". Frontiers in Oncology. 13: 1124039. doi:10.3389/fonc.2023.1124039. PMC 10010383. PMID 36923424.

Further reading

[edit]
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.